Biohaven Ltd
Company Profile
Business description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Contact
c/o Biohaven Pharmaceuticals, Inc
215 Church Street
New HavenCT06510
USAT: +1 203 404-0410
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
274
Stocks News & Analysis
stocks
ASX lisetd bank overvalued despite strong earnings
stocks
After earnings, is Amazon a buy, a sell, or fairly valued?
stocks
ASX retail share expected to recover despite choppy conditions
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,897.80 | 30.10 | -0.34% |
| CAC 40 | 8,112.57 | 89.51 | -1.09% |
| DAX 40 | 24,338.63 | 324.98 | -1.32% |
| Dow JONES (US) | 49,609.16 | 12.19 | 0.02% |
| FTSE 100 | 10,233.07 | 43.88 | -0.43% |
| HKSE | 26,393.71 | 232.57 | -0.87% |
| NASDAQ | 26,247.08 | 440.88 | 1.71% |
| Nikkei 225 | 63,216.12 | 502.47 | 0.80% |
| NZX 50 Index | 13,111.52 | 63.61 | -0.48% |
| S&P 500 | 7,398.93 | 61.82 | 0.84% |
| S&P/ASX 200 | 8,657.20 | 33.10 | -0.38% |
| SSE Composite Index | 4,179.95 | 0.14 | -0.00% |